The weight loss drug war has a $881 billion valuation gap
The obesity drug market is booming. But the stock market is treating these two companies very differently. Eli Lilly is now worth roughly $1.08 trillion. Novo Nordisk sits around $199 billion. That’s an $881 billion gap between two companies leading one of the fastest-growing drug markets in history. The obvious …